Jeffrey Travers, MD
Dermatology · Dayton, OHNPI 1770599979
Payments from drug & device makers
Across 333 payments — averaging $14,162 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1.9M
- Eli Lilly$974K
- Amgen$813K
- UCB SA$357K
- Janssen Research & Development, LLC$202K
- Kiniksa Pharmaceuticals, Ltd.$185K
- plus $332K from 11 others
Across 9 payments — averaging $7809.98 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$70K
What the payments were for
- Travel & lodging$1,65966%
- Food & beverage$79032%
- Education$502%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 16 | $1,854,250 |
| Eli Lilly | 57 | $973,642 |
| Amgen(2 entities) | 55 | $813,179 |
| UCB SA | 18 | $356,642 |
| Janssen Research & Development, LLC | 32 | $202,072 |
| Kiniksa Pharmaceuticals, Ltd. | 87 | $184,539 |
| Bristol Myers Squibb | 7 | $111,296 |
| Argenx US, Inc. | 20 | $89,882 |
| E.r. Squibb & Sons, L.L.C. | 7 | $81,162 |
| AbbVie | 4 | $18,956 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $16,226 |
| LEO Pharma AS | 4 | $11,987 |
| UCB Biosciences Inc. | 20 | $2,114 |
| LEO Pharma Inc. | 2 | $50 |
| Lilly USA, LLC | 1 | $49 |
| Incyte Corporation | 1 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bimekizumab$789
- Otezla$104
How this compares
$4,716,109 in reported general payments places this provider in the 95th percentile of 460 dermatology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other dermatology in Dayton
- Rocco SerraoDayton$3M
- Matthew BakosDayton$169K
- Matthew ZirwasBexley$7.4M
- Neil KormanCleveland$6M
- Jennifer NashWesterville$4M
- Jessica KaffenbergerColumbus$3.2M
- Patrick ShannonBoardman$2M
- George DrewMarion$2M
- Benjamin BoguckiColumbus$2M
- Michelle ChambersColumbus$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.